ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Animal models"

  • Abstract Number: 2550 • 2015 ACR/ARHP Annual Meeting

    Metabolomic Profiling of Joints in Murine Models of Inflammatory Arthritis

    Ilya gertsman1, Jesus Rivera-Nieves2, Maripat Corr2, Bruce Barshop1 and Monica Guma3, 1pediatrics, University of California, San Diego, La Jolla, CA, 2Medicine, University of California, San Diego, La Jolla, CA, 3Pharmacology, University of California, San Diego, La Jolla, CA

    Background/Purpose: Given the complexity and heterogeneous nature of rheumatoid arthritis (RA), it is unlikely that a single biomarker may provide sufficient discrimination; therefore biomarker signatures…
  • Abstract Number: 3104 • 2015 ACR/ARHP Annual Meeting

    Abnormal DNA Methylation in a Novel PTPN11 Enhancer Increases Destructive Potential of Rheumatoid Arthritis (RA) Fibroblast-like Synoviocytes (FLS) and Joint Inflammation

    Keisuke Maeshima1, Stephanie M. Stanford2, Deepa Hammaker1, Cristiano Sacchetti2, Rizi Ai3, Vida Zhang4, David L. Boyle5, Lifan Zeng6, German Muench7, Gen-Sheng Feng8, John Whitaker9, Zhong-Yin Zhang6, Wei Wang10, Nunzio Bottini2 and Gary S. Firestein5, 1Division of Rheumatology, Allergy and Immunology, UCSD School of Medicine, La Jolla, CA, 2Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 3Chemistry and Biochemistry, UC San Diego, La Jolla, CA, 4Division of Cellular Biology, La Jolla Institute for Allergy and Immunology, La Jolla, CA, 5Division of Rheumatology, Allergy and Immunology, University of California, San Diego, La Jolla, CA, 6Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN, 7La Jolla Institute for Allergy and Immunology, La Jolla, CA, 8Pathology and Division of Biological Sciences, UC San Diego, La Jolla, CA, 9Janssen Pharmaceuticals, La Jolla, CA, 10Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA

    Background/Purpose: Rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS) mediate disease pathogenesis by invading the joint extracellular matrix. The PTPN11 gene, encoding the tyrosine phosphatase SHP-2, is overexpressed…
  • Abstract Number: 936 • 2015 ACR/ARHP Annual Meeting

    IL-1 Receptor Antagonist Maintains Intestinal Microbial Homeostasis to Prevent Overt Toll-like Receptor 4-Dependent Intestinal Th17 Differentiation and Autoimmune Arthritis

    Rebecca Rogier1, Tom Ederveen1, Jos Boekhorst2, Harm Wopereis3, Johan Garssen4, Peter van der Kraan5, Sacha van Hijum2, Marije Koenders6, Wim van den Berg6 and Shahla Abdollahi-Roodsaz7,8, 1Rheumatology Research and Advanced Therapeutics, Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, 2Centre for Molecular Bioinformatics Nijmegen (CMBI), Radboud university medical center, Nijmegen, Netherlands, 3Danone Research, Wageningen, Netherlands, 4Danone Nutricia Research, Utrecht, Netherlands, 5Rheumatology Research & Advanced Therapeutics, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 6Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, 7Medicine, NYU School of Medicine, New York, NY, 8Rheumatology, Radboud university medical center, Nijmegen, Netherlands

    Background/Purpose: Interleukin-1 (IL-1) plays a pivotal role in inflammation and immunity. Activation of IL-1 receptor is physiologically inhibited by the IL-1 receptor antagonist (IL-1Ra). Mice…
  • Abstract Number: 2551 • 2015 ACR/ARHP Annual Meeting

    Antibodies to Malondialdehyde-Acetaldhyde Adducts Are Increased in the Serum of Mice Following Infection with P. Gingivalis and/or Injection of Citrullinated Mouse Type II Collagen:  a Model of Human Disease Response

    Geoffrey M. Thiele4, Einstein Juma1, Roxanne Haslam1, Michael J. Duryee2, Anand Dusad3, Carlos D. Hunter2, James R. O'Dell4, Lynell W. Klassen4, Ted R. Mikuls4 and Geoffrey M. Thiele4, 1University of Nebraska Medical Center, Omaha, NE, 2Internal Medicine Division of Rheumatology, University of Nebraska Medical Center, Omaha, NE, 3Rheumatology, University of Nebraska Medical Center, Omaha, NE, 4Veteran Affairs Nebraska-Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Patients with RA complicated by periodontal disease (PD) have been shown to have higher anti-citrullinated protein antibody (ACPA) levels, which have also become predictive…
  • Abstract Number: 3131 • 2015 ACR/ARHP Annual Meeting

    Interferon Regulatory Factor 7 (IRF7): The Possible Link Between Inflammation and Fibrosis in SSc Pathogenesis

    Minghua Wu1, Gloria Salazar1, Xiaodong Zhou2, Xinjian Guo2, John D. Reveille3, Sandeep K. Agarwal4, Michael R. Blackburn5, Maureen D Mayes1 and Shervin Assassi1, 1Rheumatology, University of Texas Medical School at Houston, Houston, TX, 2Internal Medicine, University of Texas Medical School at Houston, Houston, TX, 3Internal Medicine/Rheumatology, University of Texas Medical School at Houston, Houston, TX, 4Internal Med, Rheumatology, Baylor College of Medicine, Houston, TX, 5Biochemistry and Molecular Biology, The University of Texas Medical School at Houston, Houston, TX

    Background/Purpose: A recent global gene expression profile study in a large early SSc patient samples revealed a type I interferon (IFN) signature. Type I IFN…
  • Abstract Number: 1016 • 2015 ACR/ARHP Annual Meeting

    Collagen Antibodies Induce Pain-like Behavior in Mice Independent of Inflammation and Complement Activation but Requires Fcγrs

    Gustaf Wigerblad1, Katalin Sandor1, Kutty Selva Nandakumar2, Rikard Holmdahl3 and Camilla Svensson1, 1Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden, 2Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden, 3Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden

    Background/Purpose: Collagen Antibody Induced Arthritis (CAIA) is an acute mouse model of rheumatoid arthritis (RA). It is induced by an intravenous injection of a cocktail…
  • Abstract Number: 2552 • 2015 ACR/ARHP Annual Meeting

    Alterations in the Colonic Microbiome Precede the Development of Murine Inflammatory Arthritis

    Jason Hendrickson1, Gaurav Mehta2, NIRMAL BANDA1 and Kristine A. Kuhn1, 1University of Colorado School of Medicine, Aurora, CO, 2Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO

    Background/Purpose: Alterations in resident bacteria, termed dysbiosis, is present in patients in early stages of rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis. However, it remains unclear…
  • Abstract Number: 3190 • 2015 ACR/ARHP Annual Meeting

    Netrin-1 and Its Receptor Unc5b Are Novel Targets for the Treatment of Inflammatory Arthritis

    Aranzazu Mediero1, Tuere Wilder2 and Bruce Cronstein3, 1Medicine, Divison of Translational Medicine, NYU School of Medicine, New York City, NY, 2Dept of Med, Div of Rheum, NYU School of Medicine, New York, NY, 3Medicine, Division of Rheumatology, NYU School of Medicine, NEW YORK, NY

    Background/Purpose: Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation and destruction of the joints and some extra-articular tissues. Netrin-1 is a laminin-like…
  • Abstract Number: 1034 • 2015 ACR/ARHP Annual Meeting

    Immunomodulation By a Second-Generation Peptidyl Arginine Deiminase Inhibitor Abrogates Collagen-Induced Arthritis in a Therapeutic Protocol

    Anne-Marie Quirke1, Joanna Kawalkowska2, Fatemeh Ghari3, Venkataraman Subramaniam4, Paul Thompson5, Richard O. Williams1, Nick La Thangue3 and Patrick J. Venables1, 1Kennedy Institute of Rheumatology, University of Oxford, Oxford, United Kingdom, 2Kennedy Institute for Rheumatology, University of Oxford, Oxford, United Kingdom, 3Department of Oncology, University of Oxford, Oxford, United Kingdom, 4Biochemistry and Molecular Pharmacology, University of Massachusetts, Worcester, MA, 5University of Massachusetts, Worcester, MA

    Background/Purpose: Citrullination is a post translational modification of arginine catalysed by peptidyl arginine deiminases (PADs) and may be important in generating pathogenic autoantibodies to citrullinated…
  • Abstract Number: 2555 • 2015 ACR/ARHP Annual Meeting

    14-3-3η As a Novel RA Drug Target: Anti-14-3-3η Monoclonal Antibody Delays the Onset and Mitigates the Severity of Arthritis in CIA Mice

    Abedelnasser Abulrob1, Mario Mercier1, Slavisa Corluka1, Roger MacKenzie1, Shalini Raphael1, Sara Michienzi2, Jane Savill2, Yuan Gui2, Walter Maksymowych3 and Anthony Marotta2, 1National Research Council of Canada, Ottawa, ON, Canada, 2Augurex Life Sciences Corp., Vancouver, BC, Canada, 3Department of Medicine, University of Alberta, Edmonton, AB, Canada

    Background/Purpose: As an extracellular ligand, 14-3-3η potently and concentration-dependently upregulates the expression of multiple factors including TNFα, IL-6, and RANKL and its clinical detection is…
  • Abstract Number: 3191 • 2015 ACR/ARHP Annual Meeting

    Siglec9 Suppresses Arthritis in Collagen-Induced Mice Model and Inhibits M1 Activation of RAW264.7 Macrophages

    Takuya Matsumoto1, Nobunori Takahashi1, Toshihisa Kojima1 and Naoki Ishiguro2, 1Department of Orthopedic Surgery, Nagoya University Hospital, Nagoya, Japan, 2Department of Orthopedic Suregery, Nagoya University Hospital, Nagoya, Japan

    Background/Purpose: Siglecs (Sialic acid-binding immunoglobulin-type lectins) are type1 transmembrane proteins and expressed on cell surface of various immunocytes. Siglec9 is a member of CD33 related…
  • Abstract Number: 1053 • 2015 ACR/ARHP Annual Meeting

    Phosphatidylinositol-3-Kinase Delta Pathway a Novel Therapeutic Target for Sjogren’s Syndrome

    Saba Nayar1, Joana Campos1, Christopher Buckley1, Rodger Allen2, W.A. Fahy2, Andrew Payne2 and Francesca Barone1, 1University of Birmingham, Rheumatology Research Group, Birmingham, United Kingdom, 2UCB Pharma, Slough, United Kingdom

    Background/Purpose: Sjögren’s syndrome (SS) is a chronic autoimmune disease characterized by B cell hyper-activation and exocrine gland infiltration that results in loss of glandular function,…
  • Abstract Number: 2557 • 2015 ACR/ARHP Annual Meeting

    Comparable Therapeutic Potential of Umbilical Cord Mesenchymal Stem Cells in Collagen Induced Arthritis with Anti-Tumor Necrosis Factor or Anti-CD20

    Yue Sun, Wei Kong, Weiwei Chen, Genhong Yao, Xuebing Feng and Lingyun Sun, Department of Rheumatology and Immunology, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China

    Background/Purpose: Tremendous progress has been made in the development of non-conventional therapies for rheumatoid arthritis (RA). Mesenchymal stem cells (MSC) present multiple immunosuppressive capacities and…
  • Abstract Number: 3192 • 2015 ACR/ARHP Annual Meeting

    KCa3.1 Ion Channel in the Pathogenesis of Rheumatoid Arthritis: KCa3.1-/- Mice Do Not Develop CIA

    Siba Raychaudhuri1, Smriti K. Raychaudhuri2 and Heike Wulff3, 1Med/Rheumatology, Univ California Davis/VA Sacramento, Davis, CA, 2Rheumatology/Immunology, VA Sacramento Medical Center, Davis, CA, 3Pharmacology, UC Davis School of Medicine, Davis, CA

    Background/Purpose: KCa3.1 is a Ca2+-activated K+ channel that modulates Ca2+-dependent signaling processes such as activation and cellular proliferation. KCa3.1 is expressed in CCR7+ naïve and…
  • Abstract Number: 1106 • 2015 ACR/ARHP Annual Meeting

    Efficacy of Abbv-105, a Selective and Irreversible Inhibitor of Bruton’s Tyrosine Kinase (BTK), in Multiple Models of Inflammation

    Christian Goess1, Candace Graff2, Ting Ting Zhang2, Gregory Preston2, Richard McCarthy1, Matthew Perham1, Jacqueline Loud1, Christopher M. Harris1, Sara Murdock1, Erik Sampson3, Michael Hoemann4, Michael Friedman4, Robert Talanian3, Jeremy Edmunds4 and Andrew Long1, 1Immunology Pharmacology, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 2DMPK, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 3AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 4Chemistry, AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA

    Background/Purpose: Bruton’s Tyrosine Kinase (BTK) is a non-receptor tyrosine kinase required for intracellular signaling pathways downstream of several key immunoreceptors, including the B cell receptor,…
  • « Previous Page
  • 1
  • …
  • 10
  • 11
  • 12
  • 13
  • 14
  • …
  • 25
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology